论文部分内容阅读
目的评估使用非顺应性球囊后扩张对经置入药物洗脱支架冠状动脉粥样硬化性心脏病(以下简称冠心病)患者的疗效。方法回顾性分析2011年1月至2011年5月共356例行药物洗脱支架植入且使用非顺应性球囊后扩张的患者,采用倾向性评分抽取同期356例行药物洗脱支架植入术而未后扩张的患者与之1∶1匹配。结果 2组在年龄、性别、临床表现、主要危险因素及冠状动脉病变特征方面比较,差异无统计学意义(P>0.05),具有可比性。平均随访时间18个月,后扩张组主要不良心血管事件(major adverse cardiac events,MACE)明显低于未后扩张组(10.1%vs 15.7%,P=0.020),主要是靶血管重建(6.2%vs10.7%,P=0.010)、支架内血栓(1.1%vs 3.7%,P=0.030)发生率比较,差异有统计学意义(P<0.05),而心肌梗死(3.9%vs4.6%,P=0.700)、死亡(1.1%vs 1.7%,P=0.760)比较,差异没有统计学意义。结论冠心病患者置入药物洗脱支架后使用非顺应性球囊后扩张安全,可改善患者的临床预后。
Objective To assess the efficacy of non-compliant balloon dilatation in patients with coronary atherosclerotic heart disease (hereinafter referred to as coronary heart disease) undergoing stent placement. Methods A total of 356 patients undergoing elective stent implantation and non-compliant balloon dilatation after January 2011 to May 2011 were retrospectively analyzed. Ten hundred and sixty-six patients undergoing simultaneous drug-eluting stent implantation Patients who did not postoperatively dilated matched 1: 1. Results There were no significant differences between the two groups in age, gender, clinical manifestations, major risk factors and coronary artery lesions (P> 0.05). The mean follow-up time was 18 months. The major adverse cardiac events (MACE) in the post-dilatation group were significantly lower than those in the non-dilated group (10.1% vs 15.7%, P = 0.020) vs10.7%, P = 0.010). The incidence of stent thrombosis (1.1% vs 3.7%, P = 0.030) had statistical significance (P <0.05) P = 0.700), death (1.1% vs 1.7%, P = 0.760), the difference was not statistically significant. Conclusion Coronary heart disease patients with non-compliant balloon after stent placement safe expansion, can improve the clinical prognosis of patients.